IMMP - プリマ・バイオメッド （Immutep Limited）

Barclays launched its coverage on the U.K.-based biotech Immunocore Holdings (IMMP) on Wednesday with an Overweight rating and an $80 per share target as the company prepares to share…

Australia-based biotech Immutep Limited (IMMP) announced on Tuesday a clinical trial and supply agreement with Pfizer (PFE) and Merck KGaA (MKGAF) (MKKGY) to run a Phase 1 study for…

SYDNEY, AUSTRALIA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, is pleased to announce it has signed a Clinical Trial Collaboration and Supply Agreement (“Agreement”) with Merck KGaA, Darmstadt, Germany and Pfizer for a new Phase I clinical study in patients with urothelial cancer, called INSIGHT-005.

https://www.investing.com/news/pro/clsa-reiterates-buy-1-rating-on-immutep-ltd-432SI-2907520

SYDNEY, AUSTRALIA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announced the United States Food and Drug Administration (FDA) has granted Fast Track designation to eftilagimod alpha (“efti” or “IMP321”) in combination with pembrolizumab for the treatment of 1 st line non-small cell lung cancer (NSCLC). Efti is the Company’s first-in-class soluble LAG-3 clinical stage candidate which activates antigen presenting cells (APC) to engage both the innate and adaptive immune system to target solid tumors.

SYDNEY, AUSTRALIA, June 27, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new data from second line non-small cell lung cancer patients (Part B) in the Phase II TACTI-002 trial has been selected for a poster presentation at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) taking place in-person and online from 6-9 August 2022 in Vienna, Austria.

The following slide deck was published by Immutep Limited in conjunction with this event.

Australian biotech Immutep Limited (IMMP) announced new data from its Phase II TACTI-002 trial on Friday, highlighting the efficacy of its lead candidate eftilagimod alpha in…

The following slide deck was published by Immutep Limited in conjunction with this event.

New York, USAMetastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | De, May 24, 2022 (GLOBE NEWSWIRE) -- Metastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | DelveInsight Metastatic Breast Cancer Pipeline involves 120+ key companies continuously working towards developing 120+ Metastatic Breast Cancer treatment therapies, as per DelveInsight DelveInsight''s '' Metastatic Breast Cancer Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Metastatic Breast Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Metastatic Breast Cancer pipeline domain. Key Takeaways from the Metastatic Breast Cancer Pipeline Report DelveInsight''s Metastatic Breast Cancer Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Metastatic Breast Cancer treatment.

Gainers: Knightscope KSCP +52%. Immutep Limited (IMMP) +4%

Immutep Limited (NASDAQ:IMMP) was the recipient of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 118,900 shares, a decrease of 44.3% from the November 15th total of 213,300 shares. Based on an average daily volume of 347,300 shares, the short-interest ratio is currently []

SYDNEY, AUSTRALIA, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has signed a Manufacturing Service Agreement (MSA) with Northway Biotech, an end-to-end biopharmaceutical contract development and manufacturing organisation (CDMO), to manufacture IMP761 ahead of clinical testing.

Goldman Sachs Group Inc. purchased a new stake in shares of Immutep Limited (NASDAQ:IMMP) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 36,282 shares of the biotechnology companys stock, valued at approximately $140,000. A number of other institutional investors and hedge []

Immutep Limited (NASDAQ:IMMP) concluded the trading at $3.09 on Friday, December 03 with a fall of -8.04% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.36 and 5Y monthly beta was reading 1.45 with its price kept floating in the range Immutep Limited (IMMP) Offers An Excellent Investment Opportunity At Current Levels Read More »